Reviewing Caribou Biosciences (NASDAQ:CRBU) and Titan Pharmaceuticals (NASDAQ:TTNP)

Caribou Biosciences (NASDAQ:CRBU) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Caribou Biosciences and Titan Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-372.78%	-34.76%	-29.58%
Titan Pharmaceuticals	N/A	-87.90%	-75.11%

Institutional and Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Caribou Biosciences and Titan Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$34.48 million	7.21	-$102.07 million	($1.39)	-1.98
Titan Pharmaceuticals	$180,000.00	20.73	-$5.57 million	N/A	N/A

Titan Pharmaceuticals has lower revenue, but higher earnings than Caribou Biosciences.

Risk and Volatility

Caribou Biosciences has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Caribou Biosciences and Titan Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	1	3	0	2.75
Titan Pharmaceuticals	0	0	0	0	0.00

Caribou Biosciences presently has a consensus target price of $11.25, suggesting a potential upside of 309.09%. Given Caribou Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Titan Pharmaceuticals.

Summary

Caribou Biosciences beats Titan Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.